Evidence map›Paper›PMID 26049158›Full record

ArticleMutagenesis2016

Comparison of in vitro and in vivo clastogenic potency based on benchmark dose analysis of flow cytometric micronucleus data.

Jeffrey C Bemis, John W Wills, Steven M Bryce, Dorothea K Torous, Stephen D Dertinger, Wout Slob

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Mutagenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Comparative Genotoxicity of TEMPO and 3 of Its Derivatives in Mouse Lymphoma Cells.Toxicological sciences : an official journal of the Society of Toxicology · 2018
    Article
  10. Article
  11. Article
  12. Update: use of the benchmark dose approach in risk assessment.EFSA journal. European Food Safety Authority · 2017
    Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Jeffrey C Bemis
John W WillsEnvironmental Health Sciences and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, Canada and.
Steven M Bryce
Dorothea K Torous
Stephen D Dertinger
Wout SlobNational Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Litron Laboratories (United States) · USHealth Canada · CANational Institute for Public Health and the Environment · NL

Funding

Validation of a Rodent Mutagenicity AssayR44ES018017 · NIEHS · LITRON LABORATORIES, LTD. · PI DERTINGER, STEPHEN D · 2010 to 2012
$1.8M
Tools to Study Mammalian MutagenesisR44ES021973 · NIEHS · LITRON LABORATORIES, LTD. · PI BEMIS, JEFFREY C, DERTINGER, STEPHEN D · 2012 to 2014
$1.3M
NIEHS NIH HHS R44 ES018017NIEHS NIH HHS R44 ES021973
6 · The paper itself

Abstract

The application of flow cytometry as a scoring platform for both in vivo and in vitro micronucleus (MN) studies has enabled the efficient generation of high quality datasets suitable for comprehensive assessment of dose-response. Using this information, it is possible to obtain precise estimates of the clastogenic potency of chemicals. We illustrate this by estimating the in vivo and the in vitro potencies of seven model clastogenic agents (melphalan, chlorambucil, thiotepa, 1,3-propane sultone, hydroxyurea, azathioprine and methyl methanesulfonate) by deriving BMDs using freely available BMD software (PROAST). After exposing male rats for 3 days with up to nine dose levels of each individual chemical, peripheral blood samples were collected on Day 4. These chemicals were also evaluated for in vitro MN induction by treating TK6 cells with up to 20 concentrations in quadruplicate. In vitro MN frequencies were determined via flow cytometry using a 96-well plate autosampler. The estimated in vitro and in vivo BMDs were found to correlate to each other. The correlation showed considerable scatter, as may be expected given the complexity of the whole animal model versus the simplicity of the cell culture system. Even so, the existence of the correlation suggests that information on the clastogenic potency of a compound can be derived from either whole animal studies or cell culture-based models of chromosomal damage. We also show that the choice of the benchmark response, i.e. the effect size associated with the BMD, is not essential in establishing the correlation between both systems. Our results support the concept that datasets derived from comprehensive genotoxicity studies can provide quantitative dose-response metrics. Such investigational studies, when supported by additional data, might then contribute directly to product safety investigations, regulatory decision-making and human risk assessment.

Indexed as

DNA DamageAnimalsBenchmarkingCell LineDNADose-Response Relationship, DrugFlow CytometryIn Vitro TechniquesMaleMicronucleus TestsModels, AnimalMutagensRatsSample SizeDNAMutagens

Identifiers

PMID26049158
PMCPMC6159540
OpenAlexW1839003622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.